Newly diagnosed with low-risk prostate cancer initially confirmed by fusion guided prostate biopsy (transrectal or trans perineal) by multiparametric MRI, and had a second confirmatory biopsy within the last 12 months
Males diagnosed with low-risk prostate cancer undergoing active surveillance
Two confirmatory testosterone levels \<300 ng/dL (taken before 10am), with at least 24 hours and no more than 90 days between the two tests
Symptoms of low testosterone (Aging Male's Symptoms Score \>27)
Able to obtain Testosterone medication through insurance or out-of-pocket
Willing and able to provide written informed consent and able to comply with study requirements
You may not be if
Males \<18 years old
History of Testosterone Replacement Therapy (TRT) within the past year.
Current use of TRT
Diagnosis of Gleason score 7 (Grade Group 2) prostate cancer or higher on diagnostic or confirmatory biopsy
PSA \>10 ng/mL at baseline
Hematocrit \> 51% at baseline
T3 or T4 disease
Uncontrolled cardiovascular disease and sleep apnea
History of breast cancer
Any other condition or situation which, in the opinion of the investigator, could impact patient safety, prevent successful data collection, or reduce the likelihood of successful study participation
Unable or unwilling to obtain Testosterone medication through insurance or out-of-pocket
Unable or unwilling to provide informed consent or comply with study requirements
Clareo Health | Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
